Visilizumab

Visilizumab (marketed under the trade name Nuvion by PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn disease. Visilizumab binds to the CD3 receptor on certain activated T cells without effecting resting T cells.

External link

 * Official website

Wizylizumab